Amplify ETF Trust - Amplify Treatments, Testing and Advancements ETF Operating Income

Amplify ETF Trust - Amplify Treatments, Testing and Advancements ETF (GERM) currently reports a operating income of $510M as of June 2026. That compares with $520M in the prior-year period — down 3.6% year over year. Use the charts on this page to explore Amplify ETF Trust - Amplify Treatments, Testing and Advancements ETF's operating income history and peer comparisons.

Amplify ETF Trust - Amplify Treatments, Testing and Advancements ETF's operating income decreased from $520M to $510M — a 3.6% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Amplify ETF Trust - Amplify Treatments, Testing and Advancements ETF reported $510M in operating income as of June 2026. That compares with $520M in the prior-year period — down 3.6% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current operating income of $510M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Amplify ETF Trust - Amplify Treatments, Testing and Advancements ETF, and consider following GERM for alerts when major investors trade the stock.